🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

5,027 results for “ERA” Clear

  1. Tramadol

    AVENUE THERAPEUTICS, INC.

    Pain Management

    phase 3 small molecule active

    3 trials

  2. Tranexamic Acid

    United Therapeutics Europe Ltd

    Spinal Injuries

    phase 3 small molecule active

    1 trial

  3. Trastuzumab and neratinib

    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    Early-stage Breast Cancer

    phase 3 small molecule active

    1 trial

  4. Trazimera 420 mg powder for concentrate for solution for infusion, Perjeta 420 mg concentrate for solution for infusion, VINORELBINE ARROW 10 mg/ml, solution à diluer pour perfusion, TherO2-01S22, PACLITAXEL AHCL 6 mg/ml, solution à diluer pour perfusion, Placebo syrup, Docetaxel Accord 160 mg/8 ml concentrate for solution for infusion

    Ningbo Cancer Hospital

    metastatic breast cancer

    phase 3 small molecule active

    1 trial

  5. Treatment group

    United Therapeutics Europe Ltd

    Post Operative Surgical Site Infection

    phase 3 small molecule completed

    1 trial

  6. Treprostinil, The Placebo Nebuliser Solution is a solution dosage form for nebulisation identical to Treprostinil Nebuliser Solution drug product except for the absence of the treprostinil drug substance.

    United Therapeutics Europe Ltd

    Progressive Pulmonary Fibrosis

    phase 3 small molecule active

    1 trial

  7. Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)

    United Therapeutics Europe Ltd

    Nausea

    phase 3 small molecule active

    1 trial

  8. Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, SALBUTAMOL, Placebo MDI HFA to match BGF MDI HFA, Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension

    AstraZeneca AB

    Moderate to Severe Chronic Obstructive Pulmonary Disease(COPD)

    phase 3 small molecule active

    1 trial

  9. Trophic enteral feeding combined with supplemental parenteral nutrition

    The First People's Hospital of Lianyungang

    Severe Stroke

    phase 3 other active

    1 trial

  10. UB-421

    United Therapeutics Europe Ltd

    HIV-1 Infection

    phase 3 mab active

    4 trials

  11. UI022 or UI023 and co-administration of matching placebo

    United Therapeutics Europe Ltd

    Peripheral Arterial Disease

    phase 3 small molecule completed

    1 trial

  12. UI05MSP015CT

    United Therapeutics Europe Ltd

    Functional Dyspepsia

    phase 3 small molecule completed

    1 trial

  13. UT-15

    United Therapeutics Europe Ltd

    Pulmonary Hypertension

    phase 3 small molecule completed

    1 trial

  14. UT-15C (treprostinil diolamine)

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    phase 3 small molecule completed

    1 trial

  15. UT-15C SR

    United Therapeutics Europe Ltd

    Pulmonary Arterial Hypertension

    phase 3 small molecule completed

    3 trials

  16. UT-15C SR

    United Therapeutics Europe Ltd

    Pulmonary Hypertension

    phase 3 small molecule completed

    1 trial

  17. UVEDOSE 100 000 UI, solution buvable en ampoule

    Novo Nordisk A/S

    Thyroidectomy is a common operation. Transient postoperative hypocalcemia is the main complication, resulting in clinical discomfort for patients, longer hospital stays and increased perioperative cost. Cholecalciferol is used to supplement vitamin D deficiency. We suppose that systematic pre-operative supplementation with cholecalciferol would allow a faster and more appropriate response to post-operative hypocalcemia

    phase 3 small molecule active

    1 trial

  18. UX111

    ABEONA THERAPEUTICS INC.

    MPS IIIA

    phase 3 mab active

    1 trial

  19. Ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Multiple Sclerosis (RMS)

    phase 3 mab active

    3 trials

  20. Ublituximab

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 3 small molecule completed

    5 trials

  21. Ublituximab

    TG THERAPEUTICS, INC.

    Diffuse Large B-Cell Lymphoma

    phase 3 mab terminated

    1 trial

  22. Ublituximab

    TG THERAPEUTICS, INC.

    Relapsing Multiple Sclerosis

    phase 3 small molecule active

    3 trials

  23. Ublituximab, ublituximab

    TG THERAPEUTICS, INC.

    Relapsing forms of Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  24. Unesbulin

    PTC Therapeutics International Limited

    Leiomyosarcoma

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources